STOCK TITAN
  1. Home
  2. News
  3. NTRA

Natera, Inc. - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.

Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.

The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.

Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.

News

Invitae Completes Sale of Reproductive Health Assets to Natera

Rhea-AI Summary
Invitae (NVTA) completes the sale of reproductive health assets to Natera (NTRA) for up to $52.5 million, aiming to focus on clinical germline genetic information and reduce operating expenses by approximately $44 million annually. Natera has hired Invitae reproductive health sales representatives and will take over customer transition for non-invasive prenatal and carrier screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
News

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium. The data includes updated 24-month DFS analysis from GALAXY and first interim analysis from BESPOKE CRC. Natera and its collaborators will present 11 abstracts featuring new Signatera data across various GI indications, including two oral presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences
-
News

Natera Provides Update on Ravgen Trial

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the jury's verdict in a patent infringement lawsuit brought by Ravgen, Inc. The damages award of $57 million was significantly less than the $410 million sought by Ravgen. The jury also determined there was no willful infringement by Natera. The patent at issue has expired, and Natera plans to file an appeal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
none
News

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) expects total revenues of approximately $300 million in the fourth quarter of 2023, an increase of approximately 38% compared to $217 million in the fourth quarter of 2022. Total revenues of approximately $1.07 billion in 2023, an increase of approximately 30% compared to $820 million in 2022. These results demonstrate significant growth and surpass the top end of the company's revenue guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
-
News

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Management to deliver a presentation and host a Q&A with the investment community. Live webcast available on investor.natera.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
-
News

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) has announced that the federal District Court has issued a preliminary injunction against NeoGenomics, barring them from making, using, selling, or promoting their RaDaR molecular residual disease (MRD) assay in the United States, with limited exceptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
News

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) Announces Pan-Cancer Study Showing MTM/mL Dynamics More Predictive of Therapy Response than mVAF Dynamics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
none
-
News

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) achieves key objective as the United States District Court for the District of Delaware denies CareDx’s motion for summary judgment on two Natera patents in an infringement lawsuit. The trial will commence on January 22, 2024, as Natera aims to protect its significant investments in innovation from unlawful infringement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
News

Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) presents new data at the 2023 San Antonio Breast Cancer Symposium (SABCS) on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, showcasing leadership in personalizing patient care across the breast cancer continuum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
News

Natera Announces Real-World Data Collaboration with Merck

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) has entered into an agreement with Merck to utilize Natera’s real-world database (RWD) for oncology research. The RWD contains de-identified clinical and genomic data from over 100,000 early- and late-stage cancer patients tested with Signatera™. Pharmaceutical companies can use the RWD to advance drug development programs across early-stage and metastatic settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.38%
Tags
none

FAQ

What is the current stock price of Natera (NTRA)?

The current stock price of Natera (NTRA) is $171.82 as of January 23, 2025.

What is the market cap of Natera (NTRA)?

The market cap of Natera (NTRA) is approximately 20.8B.

What does Natera, Inc. specialize in?

Natera specializes in preconception and prenatal genetic testing services, including Non-Invasive Prenatal Testing (NIPT) and Horizon Carrier Screening (HCS).

Where is Natera, Inc. headquartered?

Natera, Inc. is headquartered in San Carlos, California.

What is the Panorama Non-Invasive Prenatal Test (NIPT)?

The Panorama NIPT screens for chromosomal abnormalities in a fetus, including twin pregnancies, typically through a blood draw from the mother.

What is the Horizon Carrier Screening (HCS)?

Horizon Carrier Screening (HCS) determines if an individual is a carrier for severe genetic diseases that could be passed to their children.

What is the Signatera Molecular Residual Disease (MRD) Test?

The Signatera MRD Test detects circulating tumor DNA in previously diagnosed cancer patients to assess molecular residual disease and monitor recurrence.

What is the purpose of the Prospera test?

The Prospera test is designed to assess organ transplant rejection.

How has Natera advanced genetic testing?

Natera has leveraged advances from the Human Genome Project and sophisticated proprietary bioinformatic algorithms to deliver highly accurate genetic testing results.

Does Natera offer genetic counseling services?

Yes, Natera provides experienced genetic counseling services to help patients understand their test results and make informed decisions.

What industries does Natera serve?

Natera primarily serves the medical diagnostics and research industries, focusing on prenatal, cancer, and transplant testing.

What makes Natera's tests unique?

Natera's tests are unique due to their high accuracy, leveraging proprietary bioinformatics technology and advances from the Human Genome Project.
Stock NTRA logo
Natera, Inc.

NYSE:NTRA

NTRA Rankings

#536 Ranked by Market Cap
N/A Ranked by Dividends

NTRA Stock Data

20.82B
126.19M
3.45%
93.38%
3.06%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
AUSTIN